Relay Therapeutics

Total Funding

$520 M


$1.4 M

FY, 2022

Relay Therapeutics Summary

Company Summary

Relay Therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. By placing protein motion at the heart of drug discovery, Relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. Headquartered in Cambridge, Mass., Relay Therapeutics is a private company launched in 2016 with $57 million in Series A venture capital financing from Third Rock Ventures and an affiliate of D.E. Shaw Research. Our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. If you're creative, collaborative and passionate about making a difference in the lives of patients, join us!
Cambridge, MA, US | view all locations
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data

Key People

  • Brian Adams

    Brian Adams, General Counsel

    • Tom Catinazzo

      Tom Catinazzo, Vice President, Finance

      • Don Bergstrom

        Don Bergstrom, Executive Vice President, Head of Research and Development

        • Dorothee Kern

          Dorothee Kern, Founder

          LocationsView all

          1 location detected

          • Cambridge, MA HQ

            United States

            399 Binney St 2nd Floor

          Relay Therapeutics Financials

          Summary Financials

          Revenue (Q3, 2023)
          Net income (Q3, 2023)
          Cash (Q3, 2023)
          EBIT (Q3, 2023)

          Footer menu